Comparative real-world effectiveness of ustekinumab versus anti-TNF in Crohn’s disease: 12-month maintenance phase results from the prospective, observational RUN-CD study using propensity score adjustment
- 25 March 2025
- journal article
- Published by Oxford University Press (OUP) in Journal of Crohn's and Colitis
- Vol. 19 (4)
Abstract
Background: The prospective RUN-CD registry investigates the effectiveness of ustekinumab (UST) and other biologics in Crohn’s disease (CD) across Germany. Based on data from the registry, this study presents the maintenance phase results of a 12-month real-world-evidence (RWE) comparison of CD patients initiating new biologic therapies with UST or anti-TNF. Methods: After excluding patients using biologics other than UST and anti-TNF and those with missing outcomes, the final sample consisted of 618 CD patients. Clinical remission (CR), defined as a Harvey-Bradshaw Index (HBI) ≤4, was the prespecified endpoint at 12 months. Switching to another biologic therapy was considered an outcome failure. Propensity score adjustment was used to reduce the effect of confounders. Results: The study included 343 CD patients treated with UST and 264 treated with anti-TNF. Over 12 months, the frequency of therapy switches was significantly higher for infliximab (28%) compared with UST (17%) and adalimumab (17%) (P =.045). There was no significant difference in CR rates at 12 months between the UST and anti-TNF groups (65.8% vs 60.0%, P =.262). However, in week-16 responders, CR rates at 12 months were significantly higher with UST (77.6%) versus anti-TNF (65.4%) (P =.041). The change in EQ-VAS (QoL) scores between UST and anti-TNF showed a 5.1-point difference favoring UST (P =.002). Conclusions: In this 12-month RWE comparison, overall CR rates were similar between UST and anti-TNF. However, among week-16 responders, CR rates were significantly higher with UST. Additionally, UST was associated with a significantly greater improvement in QoL compared with anti-TNF.Keywords
Funding Information
- Janssen-Cilag GmbH, Neuss, Germany
- Competence Network IBD
This publication has 30 references indexed in Scilit:
- Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trialThe Lancet, 2022
- Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trialThe Lancet Gastroenterology & Hepatology, 2022
- STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBDGastroenterology, 2021
- Indicators of active disease and steroid dependency in patients with inflammatory bowel diseases not treated with biologics in a German real-world-settingInternational Journal of Colorectal Disease, 2020
- Effectiveness and safety of Ustekinumab for Crohn's disease; systematic review and pooled analysis of real-world evidenceDigestive and Liver Disease, 2019
- Subcutaneous Ustekinumab Provides Clinical Benefit for Two-Thirds of Patients With Crohn’s Disease Refractory to Anti–Tumor Necrosis Factor AgentsClinical Gastroenterology and Hepatology, 2016
- Addressing unmet needs in inflammatory bowel diseaseDrug Discovery Today, 2015
- Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studiesStatistics in Medicine, 2015
- Aktualisierte S3-Leitlinie – „Diagnostik und Therapie des Morbus Crohn“ 2014Zeitschrift für Gastroenterologie, 2014
- Drawing Causal Inferences Using Propensity Scores: A Practical Guide for Community PsychologistsAmerican Journal of Community Psychology, 2013